Furthermore, clinical and experimental studies show that the efficacy of the three currently licensed anti-TNF agents (infliximab, etanercept and adalimumab) may vary and depend on the type of ...

Etanercept, adalimumab and infliximab are the ... Systemic-onset juvenile idiopathic arthritis responds less well to anti-TNF-α therapy. IL-1 blockers such as anakinra and more recently ...

2 In our clinical experience, approximately 20% of patients with moderate-to-severe psoriasis are currently treated with anti-TNF agents including etanercept, infliximab and adalimumab.

adds specificity by showing a moderately increased risk of herpes zoster in patients receiving anti-TNF antibody ... treated with the TNF receptor fusion protein etanercept, although this increase ...

Researchers separated biologics targeting IL-12, IL-23, and IL-17 from anti-TNF biologics, including adalimumab, etanercept, and infliximab. Findings showed that IL-targeting biologics were ...